crossover randomized trial

S003107

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Type 2 diabetes (adults)Chronic kidney disease with diabetesS003107

Design

Randomized: 10
Start year
Treatment
Countries: Japan
Sponsor: Ministry of Health, Labour and Welfare, Japan (non industry)
Eligibility: insulin treated T2D on hemodialysis; S-CPR at least 2.0; insulin up to 20 U/day

Conduct and analysis

Blinding: not reported
Sequence generation: not reported
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed
A1	liraglutide Liraglutide 0.3 mg	hemodialysis thrice weekly; lifestyle: not reported	10	10
A2	Vildagliptin Vildagliptin 50 mg	hemodialysis thrice weekly; lifestyle: not reported	10	10
A3	Alogliptin Alogliptin 6.25 mg	hemodialysis thrice weekly; lifestyle: not reported	10	10

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Whole trial ALL
age	mean (years)	62.9
age	se (years)	4.3
bmi	mean (kg/m2)	23.0
bmi	se (kg/m2)	1.5
diabetes duration	mean (years)	25.4
diabetes duration	se (years)	2.3
established cvd	n	4
female	n	3
insulin dose	mean (U/day)	11.6
insulin dose	se (U/day)	1.9